Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.54 AUD -0.05 ( 8.47%)
Last update at 2026-09-28T06:10:00Z
VOLUME
6998875
Market Cap
496.39M

Momentum Score

…

Echo IQ Limited, an artificial intelligence (AI) and medical technology company, engages in the development and application of AI for the cardiac diagnostics sector in Australia. It offers EchoSolv, a machine-learning and AI-based clinical decision support software for use as an adjunct to echocardiography in the assessment of severe aortic stenosis and other cardiovascular conditions. The company has a research collaboration with Mayo Clinic to assess cardiac risk in patients receiving cancer therapy. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.54
Low
0.59
High
52 Week Price Range
0.17
Low
1.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Echoiq Ltd is an Australian-listed company (ASX: EIQ) for which publicly available materials provide limited detail on core operations and product lines. Because public disclosures are sparse, major long-term growth drivers are not clearly described; investors may find the company potentially interesting if future filings demonstrate a clear revenue model, scalable customer traction and disciplined capital allocation.
The primary investment risks are the lack of transparency and limited public information, which increase execution, liquidity and valuation uncertainty and make ongoing regulatory filings and management disclosures critical for assessment.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.59
Dividend Yield
-
Revenue TTM
0.09M
Revenue Per Share
-
Gross Profit TTM
-6.02M
Debt / Equity
-
ROE
-107.99%
Net Debt
-8.71M
ROCE
-170.68%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -18.57M -13.26M -5.41M -8.27M -6.49M
Net income -18.57M -13.26M -5.41M -8.27M -5.99M
Selling general administrative 13.70M 9.59M 4.23M 4.38M 4.24M
Selling and marketing expenses - 0.27M 0.01M 0.11M -0.90M
Gross profit -16.31M -3.14M -2.88M -7.01M -3.19M
Reconciled depreciation 0.55M - 0.60M 0.61M 0.64M
Ebit -19.85M -13.13M -5.41M -8.27M -6.53M
Ebitda -19.30M -12.74M -4.81M -7.66M -5.89M
Depreciation and amortization 0.55M 0.39M 0.60M 0.61M 0.64M
Operating income -19.85M -13.00M -5.92M -8.27M -6.53M
Other operating expenses 19.94M 13.10M 5.97M 8.37M 6.78M
Interest expense - - - - 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.52M 0.20M - - 0.00M
Net interest income 0.52M - - - -
Extraordinary items - - 0.00M 0.41M 0.50M
Income tax expense - - 0.00M 0.00M -0.50M
Total revenue 0.09M 0.10M 0.04M 0.11M 0.25M
Total operating expenses 3.54M 9.86M 3.04M 1.26M 3.34M
Cost of revenue 16.40M 3.24M 2.92M 7.12M 3.44M
Total other income expense net 1.28M -0.27M 0.51M -0.00M 0.04M
Discontinued operations - - - 0.41M 0.50M
Net income from continuing ops -18.57M - -5.41M -8.21M -6.49M
Net income applicable to common shares - -13.26M -5.41M -7.86M -6.17M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13.88M 23.37M 8.26M 10.38M 9.97M
Intangible assets 4.16M 4.69M - 6.37M 7.16M
Other current assets 0.78M 11.81M 0.24M 0.00M 0.50M
Total liab 2.25M 0.62M 1.49M 2.95M 2.13M
Total stockholder equity 11.63M 22.76M 6.77M 7.44M 7.84M
Other current liab 1.47M 0.39M 0.12M 0.01M 0.55M
Common stock 68.15M 64.62M 41.53M 36.00M 30.40M
Capital stock 68.15M - - 36.00M 30.40M
Retained earnings -65.52M -49.03M -39.10M -35.14M -27.90M
Good will - - - - 0.14M
Other assets - - - - 0.00M
Cash 8.71M 6.62M 2.12M 3.28M 2.41M
Cash and equivalents - - - - 2.41M
Total current liabilities 2.25M 0.62M 1.49M 2.95M 2.13M
Current deferred revenue 0.01M - 0.01M 0.01M 0.01M
Net debt -8.71M -6.62M -2.12M -3.28M -2.41M
Short term debt - - - 0.08M 0.04M
Other stockholder equity - - - -0.81M -2.69M
Property plant equipment - - - 0.03M 0.04M
Total current assets 9.64M 18.65M 2.45M 3.98M 2.76M
Long term investments 0.01M - - 0.00M 0.00M
Net tangible assets - - - 1.02M 1.05M
Short term investments - - - - 0.00M
Net receivables 0.15M 0.21M 0.10M 0.64M 0.36M
Accounts payable 0.76M 0.22M 1.36M 2.85M 1.53M
Accumulated other comprehensive income 9.00M 7.17M 4.33M 6.58M 5.33M
Non currrent assets other - - 5.78M 0.00M 0.00M
Non current assets total 4.23M 4.73M 5.80M 6.41M 7.21M
Long term debt total - - - 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - 0.00M -0.06M -0.37M
Change to liabilities - - - 0.05M 0.29M
Total cashflows from investing activities 11.46M -11.55M - -0.06M 0.14M
Total cash from financing activities 1.22M 22.56M 2.77M 5.88M 1.55M
Change to operating activities - - - 0.04M -0.15M
Net income -18.57M -13.26M -5.41M -8.27M -6.49M
Change in cash 2.09M 4.50M -1.16M 0.87M -1.41M
Begin period cash flow 6.62M 2.12M 3.28M 2.41M 3.81M
End period cash flow 8.71M 6.62M 2.12M 3.28M 2.41M
Total cash from operating activities -10.56M -6.51M -3.92M -4.94M -2.58M
Issuance of capital stock 1.22M - 2.76M 6.07M 1.55M
Depreciation 0.55M 0.58M 0.60M 0.61M 0.64M
Other cashflows from investing activities 11.52M -11.52M 0.00M - 0.50M
Change to inventory - - - -0.09M -0.14M
Change to account receivables 0.07M -0.11M -0.11M 0.12M -0.16M
Sale purchase of stock - - - -0.19M -0.17M
Other cashflows from financing activities - - 2.76M 0.19M 0.17M
Change to netincome - - - 2.50M 2.63M
Capital expenditures 0.05M 0.04M 0.00M 0.34M 0.37M
Change in working capital 1.21M -0.16M -0.08M 0.20M -0.02M
Stock based compensation - 6.72M 0.81M 2.38M 2.63M
Other non cash items 6.25M -0.39M 0.15M 3.56M 4.44M
Free cash flow -10.62M -6.54M -3.92M -5.28M -2.95M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EIQ
Echoiq Ltd
-0.05
8.47%
0.54 - - 5395.50 40.77 5059.22 -8.27
PME
Pro Medicus Ltd
1.15
0.71%
162.15 64.69 89.29 65.34 37.37 63.47 81.35
AYA
ARTRYA Ltd
-0.24
6.30%
3.57 - - 23230.33 8.10 20004.93 0.33
CGS
Cogstate Ltd
-0.06
1.78%
3.31 36.00 28.17 9.16 6.93 6.33 19.23
ALC
Alcidion Group Ltd
-
-%
0.10 - 1.23 2.68 1.49 2.75 18.06

Profile*

Echoiq Ltd

Echo IQ Limited, an artificial intelligence (AI) and medical technology company, engages in the development and application of AI for the cardiac diagnostics sector in Australia. It offers EchoSolv, a machine-learning and AI-based clinical decision support software for use as an adjunct to echocardiography in the assessment of severe aortic stenosis and other cardiovascular conditions. The company has a research collaboration with Mayo Clinic to assess cardiac risk in patients receiving cancer therapy. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is headquartered in Sydney, Australia.

66 Clarence Street, Sydney, NSW, Australia, 2000

61 2 9159 3719

Name Title Year Born
Mr. Andrew Grover Interim MD & Exec. Chairman NA
Jacki McAvenna Chief Financial Officer NA
Mr. Philip Woolff Chief Operating Officer NA
Sean Bryceland Chief Technology Officer NA
Prof. David Playford Chief Medical Officer- Medical Advisory Team NA
Mr. Donald L. Fowler Pres of Echo IQ USA NA
Ms. Jessamyn Sarah Lyons AGIA, B.Com. Joint Company Secreatry NA
Adam Uren Joint Company Sec. NA
Mr. Andrew Grover Interim MD & Executive Chairman NA
Mr. Donald L. Fowler President of Echo IQ USA NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…